Optimal Treatment Of Metastatic TNBC ClinicalXchange Oncology Podcasts podcast

Artwork

Innhold levert av Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

ClinicalXchange Oncology podcasts « »
Optimal Treatment of Metastatic TNBC

3y ago 29:30

Del

MP3•Episoder hjem

Innhold levert av Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Presenter:

Hope S. Rugo MD
Professor of Medicine
University of California
San Francisco Comprehensive Cancer Center

TNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subtype is very aggressive, with a median overall survival slightly greater than 1 year. Furthermore, treatment options are limited. New and innovative therapies are being evaluated in patients to improve their outcomes, including progression-free survival and time to deterioration in health-related quality of life. Here, we present an expert-led review on current standards of care, as well as novel and emerging treatment regimens that are in the pipeline for approval by the United States Food and Drug Administration and/or under investigation.

Follow along with the slideset located here:
https://bit.ly/3krD3Gj

… continue reading

4 episoder

Artwork

Optimal Treatment of Metastatic TNBC

ClinicalXchange Oncology podcasts

published 3y ago

Del

MP3•Episoder hjem

Innhold levert av Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Presenter:

Hope S. Rugo MD
Professor of Medicine
University of California
San Francisco Comprehensive Cancer Center

TNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subtype is very aggressive, with a median overall survival slightly greater than 1 year. Furthermore, treatment options are limited. New and innovative therapies are being evaluated in patients to improve their outcomes, including progression-free survival and time to deterioration in health-related quality of life. Here, we present an expert-led review on current standards of care, as well as novel and emerging treatment regimens that are in the pipeline for approval by the United States Food and Drug Administration and/or under investigation.

Follow along with the slideset located here:
https://bit.ly/3krD3Gj

… continue reading

4 episoder

Alle episoder

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema